JP2013501074A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501074A5 JP2013501074A5 JP2012523962A JP2012523962A JP2013501074A5 JP 2013501074 A5 JP2013501074 A5 JP 2013501074A5 JP 2012523962 A JP2012523962 A JP 2012523962A JP 2012523962 A JP2012523962 A JP 2012523962A JP 2013501074 A5 JP2013501074 A5 JP 2013501074A5
- Authority
- JP
- Japan
- Prior art keywords
- tert
- naphthalen
- butylcyclohexyloxy
- trans
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 12
- -1 cycloalkenylalkyl Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 125000000304 alkynyl group Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- QEKHDQGTADGOPQ-HZCBDIJESA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCCCC(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCCCC(O)=O)C=C2)C2=C1 QEKHDQGTADGOPQ-HZCBDIJESA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000004442 acylamino group Chemical group 0.000 claims 2
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000005251 aryl acyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 2
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005253 heteroarylacyl group Chemical group 0.000 claims 2
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 1
- VZQRRJNPKYSQBI-UHFFFAOYSA-N 1-[[6-(4-tert-butylcyclohexyl)oxy-8-methylnaphthalen-2-yl]methyl]azetidine-3-carboxylic acid Chemical compound C=1C2=CC=C(CN3CC(C3)C(O)=O)C=C2C(C)=CC=1OC1CCC(C(C)(C)C)CC1 VZQRRJNPKYSQBI-UHFFFAOYSA-N 0.000 claims 1
- QQSHNSVDLZXQDL-UHFFFAOYSA-N 1-[[6-(4-tert-butylcyclohexyl)oxy-8-methylnaphthalen-2-yl]methyl]pyrrolidine-3-carboxylic acid Chemical compound C=1C2=CC=C(CN3CC(CC3)C(O)=O)C=C2C(C)=CC=1OC1CCC(C(C)(C)C)CC1 QQSHNSVDLZXQDL-UHFFFAOYSA-N 0.000 claims 1
- FBCYPFYRQJHKBA-UHFFFAOYSA-N 2,2-difluoro-3-[(6-spiro[5.5]undecan-3-yloxynaphthalen-2-yl)methylamino]propanoic acid Chemical compound C1=CC2=CC(CNCC(F)(F)C(=O)O)=CC=C2C=C1OC(CC1)CCC21CCCCC2 FBCYPFYRQJHKBA-UHFFFAOYSA-N 0.000 claims 1
- CPMNPIAAJAFQSM-UHFFFAOYSA-N 2-[[6-(4-tert-butylcyclohexyl)oxy-8-methylnaphthalen-2-yl]methylamino]acetic acid Chemical compound C=1C2=CC=C(CNCC(O)=O)C=C2C(C)=CC=1OC1CCC(C(C)(C)C)CC1 CPMNPIAAJAFQSM-UHFFFAOYSA-N 0.000 claims 1
- IHVGMKPOVICRCO-UHFFFAOYSA-N 3-[[6-(4-tert-butylcyclohexyl)oxy-8-methylnaphthalen-2-yl]methylamino]propanoic acid Chemical compound C=1C2=CC=C(CNCCC(O)=O)C=C2C(C)=CC=1OC1CCC(C(C)(C)C)CC1 IHVGMKPOVICRCO-UHFFFAOYSA-N 0.000 claims 1
- UINZHPGYKUICNX-UHFFFAOYSA-N 4-[[6-(4-tert-butylcyclohexyl)oxy-8-methylnaphthalen-2-yl]methylamino]butanoic acid Chemical compound C=1C2=CC=C(CNCCCC(O)=O)C=C2C(C)=CC=1OC1CCC(C(C)(C)C)CC1 UINZHPGYKUICNX-UHFFFAOYSA-N 0.000 claims 1
- UYLGHJRDJDVQMB-MEMLXQNLSA-N C1=CC2=CC(CN(CC(O)=O)C)=CC=C2C=C1O[C@H]1CC[C@H](C(C)(C)C)CC1 Chemical compound C1=CC2=CC(CN(CC(O)=O)C)=CC=C2C=C1O[C@H]1CC[C@H](C(C)(C)C)CC1 UYLGHJRDJDVQMB-MEMLXQNLSA-N 0.000 claims 1
- WZFCXZNZEHYYKJ-HZCBDIJESA-N C1=CC2=CC(CN(CCC(O)=O)C)=CC=C2C=C1O[C@H]1CC[C@H](C(C)(C)C)CC1 Chemical compound C1=CC2=CC(CN(CCC(O)=O)C)=CC=C2C=C1O[C@H]1CC[C@H](C(C)(C)C)CC1 WZFCXZNZEHYYKJ-HZCBDIJESA-N 0.000 claims 1
- NAZCFDBQQZNGAM-USEYMLRUSA-N C1=CC2=CC(CNC(C)C(O)=O)=CC=C2C=C1O[C@H]1CC[C@H](C(C)(C)C)CC1 Chemical compound C1=CC2=CC(CNC(C)C(O)=O)=CC=C2C=C1O[C@H]1CC[C@H](C(C)(C)C)CC1 NAZCFDBQQZNGAM-USEYMLRUSA-N 0.000 claims 1
- MCQYEAGIIQZCHU-HHXQIICLSA-N C1=CC2=CC(CNC(CC(O)=O)C)=CC=C2C=C1O[C@H]1CC[C@H](C(C)(C)C)CC1 Chemical compound C1=CC2=CC(CNC(CC(O)=O)C)=CC=C2C=C1O[C@H]1CC[C@H](C(C)(C)C)CC1 MCQYEAGIIQZCHU-HHXQIICLSA-N 0.000 claims 1
- PNFHUTFZTRMUMB-HZCBDIJESA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CCCCC(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CCCCC(O)=O)C=C2)C2=C1 PNFHUTFZTRMUMB-HZCBDIJESA-N 0.000 claims 1
- GHDOPFANSFOQCO-YHBQERECSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CCCCCC(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CCCCCC(O)=O)C=C2)C2=C1 GHDOPFANSFOQCO-YHBQERECSA-N 0.000 claims 1
- RUDHUUMXNDXZOQ-RQNOJGIXSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CCCCCCC(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CCCCCCC(O)=O)C=C2)C2=C1 RUDHUUMXNDXZOQ-RQNOJGIXSA-N 0.000 claims 1
- ZWLSMKTUZSXFHA-HZCBDIJESA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2CC(C2)C(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2CC(C2)C(O)=O)C=C2)C2=C1 ZWLSMKTUZSXFHA-HZCBDIJESA-N 0.000 claims 1
- VXPJMOYGHOFZSF-MXVIHJGJSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2CC(C2)C(O)=O)C=C2)C2=C1C(F)(F)F Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2CC(C2)C(O)=O)C=C2)C2=C1C(F)(F)F VXPJMOYGHOFZSF-MXVIHJGJSA-N 0.000 claims 1
- GEYDIDQAZQLKQL-FMWDMEFWSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2CC(CC2)C(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2CC(CC2)C(O)=O)C=C2)C2=C1 GEYDIDQAZQLKQL-FMWDMEFWSA-N 0.000 claims 1
- UDEVWUIEXXADMG-RQNOJGIXSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2CCC(CC2)C(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2CCC(CC2)C(O)=O)C=C2)C2=C1 UDEVWUIEXXADMG-RQNOJGIXSA-N 0.000 claims 1
- NGXYDHHFMUXFFZ-WXFUMESZSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2C[C@@H](CCC2)C(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2C[C@@H](CCC2)C(O)=O)C=C2)C2=C1 NGXYDHHFMUXFFZ-WXFUMESZSA-N 0.000 claims 1
- NGXYDHHFMUXFFZ-HJOGWXRNSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2C[C@H](CCC2)C(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CN2C[C@H](CCC2)C(O)=O)C=C2)C2=C1 NGXYDHHFMUXFFZ-HJOGWXRNSA-N 0.000 claims 1
- FLZBIISDFKGFNY-MXVIHJGJSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCC(F)(F)C(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCC(F)(F)C(O)=O)C=C2)C2=C1 FLZBIISDFKGFNY-MXVIHJGJSA-N 0.000 claims 1
- KEFAUIVEHFXWCP-MXVIHJGJSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCC(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCC(O)=O)C=C2)C2=C1 KEFAUIVEHFXWCP-MXVIHJGJSA-N 0.000 claims 1
- MZITWAHRSCYICI-MEMLXQNLSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCCC(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCCC(O)=O)C=C2)C2=C1 MZITWAHRSCYICI-MEMLXQNLSA-N 0.000 claims 1
- RCURJBOKDLLBRG-WGSAOQKQSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCCC(O)=O)C=C2)C2=C1C(F)(F)F Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCCC(O)=O)C=C2)C2=C1C(F)(F)F RCURJBOKDLLBRG-WGSAOQKQSA-N 0.000 claims 1
- SZIIHVINOJAPFI-MEMLXQNLSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCCP(O)(O)=O)C=C2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(C=C(CNCCP(O)(O)=O)C=C2)C2=C1 SZIIHVINOJAPFI-MEMLXQNLSA-N 0.000 claims 1
- TXEIROWDNTVDNR-MXVIHJGJSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(CN(CCCC(O)=O)CC2)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(CN(CCCC(O)=O)CC2)C2=C1 TXEIROWDNTVDNR-MXVIHJGJSA-N 0.000 claims 1
- ARBAFOAUKUTDEW-IBOPQAGSSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(N(CC2)C(=O)C(N)CC(O)=O)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(N(CC2)C(=O)C(N)CC(O)=O)C2=C1 ARBAFOAUKUTDEW-IBOPQAGSSA-N 0.000 claims 1
- CZCMJVUKXUTEMK-IYARVYRRSA-N C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(N(CC2)C(=O)CNCCP(O)(O)=O)C2=C1 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(N(CC2)C(=O)CNCCP(O)(O)=O)C2=C1 CZCMJVUKXUTEMK-IYARVYRRSA-N 0.000 claims 1
- TXEIROWDNTVDNR-BGYRXZFFSA-N C1C[C@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(CN(CCCC(O)=O)CC2)C2=C1 Chemical compound C1C[C@H](C(C)(C)C)CC[C@@H]1OC1=CC=C(CN(CCCC(O)=O)CC2)C2=C1 TXEIROWDNTVDNR-BGYRXZFFSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000002682 anti-psoriatic effect Effects 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000006769 halocycloalkoxy group Chemical group 0.000 claims 1
- 125000005347 halocycloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000004954 trialkylamino group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23153909P | 2009-08-05 | 2009-08-05 | |
| US61/231,539 | 2009-08-05 | ||
| PCT/US2010/044607 WO2011017561A1 (en) | 2009-08-05 | 2010-08-05 | Bicyclic aryl sphingosine 1-phosphate analogs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032700A Division JP6347797B2 (ja) | 2009-08-05 | 2016-02-24 | 二環式アリールスフィンゴシン１−リン酸類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013501074A JP2013501074A (ja) | 2013-01-10 |
| JP2013501074A5 true JP2013501074A5 (https=) | 2013-09-12 |
| JP5893558B2 JP5893558B2 (ja) | 2016-03-23 |
Family
ID=43544674
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523962A Active JP5893558B2 (ja) | 2009-08-05 | 2010-08-05 | 二環式アリールスフィンゴシン１−リン酸類似体 |
| JP2016032700A Active JP6347797B2 (ja) | 2009-08-05 | 2016-02-24 | 二環式アリールスフィンゴシン１−リン酸類似体 |
| JP2018013613A Pending JP2018123124A (ja) | 2009-08-05 | 2018-01-30 | 二環式アリールスフィンゴシン１−リン酸類似体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016032700A Active JP6347797B2 (ja) | 2009-08-05 | 2016-02-24 | 二環式アリールスフィンゴシン１−リン酸類似体 |
| JP2018013613A Pending JP2018123124A (ja) | 2009-08-05 | 2018-01-30 | 二環式アリールスフィンゴシン１−リン酸類似体 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US8802659B2 (https=) |
| EP (1) | EP2461683B8 (https=) |
| JP (3) | JP5893558B2 (https=) |
| KR (1) | KR101818096B1 (https=) |
| CN (2) | CN105330576B (https=) |
| AU (1) | AU2010279337B2 (https=) |
| BR (1) | BR112012002511B1 (https=) |
| CA (1) | CA2768858C (https=) |
| CO (1) | CO6440523A2 (https=) |
| DK (1) | DK2461683T3 (https=) |
| EA (1) | EA024435B1 (https=) |
| ES (1) | ES2539383T3 (https=) |
| HR (1) | HRP20150792T1 (https=) |
| HU (1) | HUE025081T2 (https=) |
| IL (2) | IL217884A (https=) |
| IN (1) | IN2012DN01241A (https=) |
| ME (1) | ME02157B (https=) |
| MX (1) | MX2012001650A (https=) |
| MY (1) | MY157707A (https=) |
| NZ (1) | NZ597596A (https=) |
| PL (1) | PL2461683T3 (https=) |
| PT (1) | PT2461683E (https=) |
| RS (1) | RS54091B1 (https=) |
| SG (1) | SG177675A1 (https=) |
| SI (1) | SI2461683T1 (https=) |
| SM (1) | SMT201500170B (https=) |
| UA (1) | UA107360C2 (https=) |
| WO (1) | WO2011017561A1 (https=) |
| ZA (1) | ZA201200505B (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2613739T3 (es) * | 2008-10-30 | 2017-05-25 | Biogen Ma Inc. | Análogos heterobicíclicos de 1-fosfato de esfingosina |
| US9181191B2 (en) | 2008-10-30 | 2015-11-10 | Biogen Ma Inc. | Heterobicyclic sphingosine 1-phosphate analogs |
| US8269043B2 (en) | 2008-10-30 | 2012-09-18 | Biogen Idec Ma Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
| RU2572826C2 (ru) | 2008-12-02 | 2016-01-20 | Чиралджен, Лтд. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| UA113507C2 (xx) | 2011-02-07 | 2017-02-10 | Модулятори s1p | |
| CN102212007A (zh) * | 2011-04-11 | 2011-10-12 | 启东东岳药业有限公司 | 高纯度2-羟甲基丙烯酸甲酯的制备方法 |
| KR101299512B1 (ko) * | 2011-04-19 | 2013-08-22 | 전북대학교산학협력단 | 스핑고신 1-포스페이트를 유효성분으로 함유하는 관절염 질환 치료 조성물 |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| EA026655B1 (ru) | 2011-09-15 | 2017-05-31 | Новартис Аг | 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ |
| WO2013093850A1 (en) * | 2011-12-22 | 2013-06-27 | Novartis Ag | Quinoline derivatives |
| IN2014DN09346A (https=) | 2012-06-13 | 2015-07-17 | Hoffmann La Roche | |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| US9555050B2 (en) * | 2012-07-27 | 2017-01-31 | Biogen Ma Inc. | ATX modulating agents |
| MX363388B (es) | 2012-07-27 | 2019-03-20 | Biogen Ma Inc | Agentes moduladores de autotaxina. |
| EA027809B1 (ru) * | 2012-07-27 | 2017-09-29 | Биоген Айдек Ма Инк. | Соединения, которые являются s1p-модулирующими агентами и/или atx-модулирующими агентами |
| WO2014025708A1 (en) * | 2012-08-06 | 2014-02-13 | Biogen Idec Ma Inc. | Compounds that are s1p modulating agents and/or atx modulating agents |
| WO2014025709A1 (en) | 2012-08-06 | 2014-02-13 | Biogen Idec Ma Inc. | Compounds that are s1p modulating agents and/or atx modulating agents |
| KR102179599B1 (ko) | 2012-09-25 | 2020-11-19 | 에프. 호프만-라 로슈 아게 | 이환형 유도체 |
| WO2014081756A1 (en) | 2012-11-20 | 2014-05-30 | Biogen Idec Ma Inc. | S1p and/or atx modulating agents |
| CA2899322A1 (en) * | 2013-01-29 | 2014-08-07 | Biogen Ma Inc. | S1p modulating agents |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| CN105764905B (zh) | 2013-11-26 | 2019-06-07 | 豪夫迈·罗氏有限公司 | 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基 |
| ES2917473T3 (es) | 2014-01-16 | 2022-07-08 | Wave Life Sciences Ltd | Diseño quiral |
| CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
| WO2015144609A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| RU2743074C2 (ru) | 2014-08-01 | 2021-02-15 | Нуэволюшон А/С | Соединения, активные по отношению к бромодоменам |
| ES2852724T3 (es) * | 2014-12-04 | 2021-09-14 | Ono Pharmaceutical Co | Derivados de dihidronaftaleno útiles en el tratamiento de enfermedades mediadas por S1P5 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| AU2016270373A1 (en) | 2015-06-05 | 2018-01-04 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
| EP3341369A1 (en) * | 2015-08-28 | 2018-07-04 | AbbVie Inc. | Fused heterocyclic compounds as s1p modulators |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| CR20180057A (es) | 2015-09-24 | 2018-04-02 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. |
| AU2016328365B2 (en) | 2015-09-24 | 2020-04-23 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| KR20180054830A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서의 이환형 화합물 |
| RU2018112230A (ru) | 2015-09-24 | 2019-10-30 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов atx |
| CN106336357A (zh) * | 2016-08-29 | 2017-01-18 | 启东东岳药业有限公司 | 2‑羟甲基丙烯酸甲酯的制备方法 |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| SG11201908560SA (en) | 2017-03-16 | 2019-10-30 | Hoffmann La Roche | Heterocyclic compounds useful as dual atx/ca inhibitors |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| US20210147381A1 (en) | 2017-07-17 | 2021-05-20 | AbbVie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as sip modulators |
| HUE068382T2 (hu) | 2018-02-22 | 2024-12-28 | Ono Pharmaceutical Co | SIP5-receptor-agonista aktivitással rendelkezõ 1[[(3S)-3-metil-6-(4(4,4-trifluorbutoxi)-3,4-dihidronaftalen-2-il]metil]azetidin-3-karbonsav neurodegeneratív rendellenességek és rák kezelésére |
| DE102018105524A1 (de) * | 2018-03-09 | 2019-09-12 | Universität Duisburg-Essen | Verwendung von Modulatoren der Sphingosin-1-phosphat-Signaltransduktion |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| WO2020081852A1 (en) * | 2018-10-17 | 2020-04-23 | The Research Foundation For The State University Of New York | Selective ship inhibitors for treating disease |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| AU2020220333B2 (en) | 2019-02-11 | 2025-10-16 | Merck Patent Gmbh | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| KR102823056B1 (ko) | 2019-06-18 | 2025-06-23 | 화이자 인코포레이티드 | 벤즈이속사졸 설폰아마이드 유도체 |
| AU2020333225B2 (en) | 2019-08-16 | 2026-04-23 | Cyclacel Limited | Process for the preparation of a pyrimidino-diazepine derivative |
| CN114302873A (zh) | 2019-08-20 | 2022-04-08 | 小野药品工业株式会社 | 具有s1p5受体激动活性的化合物的盐和晶形 |
| BR112022010761A2 (pt) * | 2019-12-03 | 2022-08-23 | Lg Chemical Ltd | Agonista do receptor de esfingosina-1-fosfato, método de preparação do mesmo e composição farmacêutica contendo o mesmo como ingrediente ativo |
| KR102806315B1 (ko) * | 2021-04-14 | 2025-05-13 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| CN117120425A (zh) * | 2021-04-14 | 2023-11-24 | 株式会社Lg化学 | 鞘氨醇-1-磷酸酯受体激动剂的晶体形式 |
| KR102806317B1 (ko) * | 2021-04-14 | 2025-05-13 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| WO2022220600A1 (ko) * | 2021-04-14 | 2022-10-20 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제의 결정형 |
| EP4306514A4 (en) * | 2021-04-14 | 2024-09-11 | Lg Chem, Ltd. | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR THE SYNTHESIS OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST |
| KR102658761B1 (ko) * | 2021-04-14 | 2024-04-19 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 |
| JP7767453B2 (ja) * | 2021-04-14 | 2025-11-11 | エルジー・ケム・リミテッド | スフィンゴシン－１－リン酸受容体アゴニストの薬学的に許容される塩及びその結晶形 |
| KR20240035820A (ko) | 2021-07-09 | 2024-03-18 | 플렉시움 인코포레이티드 | Ikzf2를 조절하는 아릴 화합물 및 약학 조성물 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2555571B1 (fr) | 1983-11-28 | 1986-11-28 | Interna Rech Dermatolo Centre | Derives du naphtalene, leur procede de preparation et leur application dans le domaine therapeutique |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004092144A2 (en) * | 2003-04-16 | 2004-10-28 | F. Hoffmann-La Roche Ag | Quinazoline compounds useful as p38 kinase inhibitors |
| CN1791592B (zh) * | 2003-05-19 | 2012-07-04 | Irm责任有限公司 | 免疫抑制剂化合物和组合物 |
| BRPI0410439A (pt) * | 2003-05-19 | 2006-06-06 | Irm Llc | compostos e composições imunossupressoras |
| CA2528232C (en) | 2003-06-06 | 2010-05-25 | Fibrogen, Inc. | Novel nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005014533A2 (en) * | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| EP1661881B1 (en) | 2003-08-29 | 2014-12-17 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding s1p receptor and pharmaceutical use thereof |
| CN1874991A (zh) * | 2003-08-29 | 2006-12-06 | 小野药品工业株式会社 | 能够结合s1p受体的化合物及其药物用途 |
| EP1541143A1 (en) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Dpp-iv inhibitors |
| GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| JPWO2005082905A1 (ja) | 2004-02-26 | 2007-08-02 | 協和醗酵工業株式会社 | 二環性複素環化合物 |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| EP2592066B1 (en) | 2004-12-13 | 2014-12-03 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medical use thereof |
| WO2006080477A1 (en) | 2005-01-25 | 2006-08-03 | Tanabe Seiyaku Co., Ltd. | Norvaline derivative and method for preparation thereof |
| AU2006214314B2 (en) * | 2005-02-14 | 2012-02-09 | University Of Virginia Patent Foundation | Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups |
| AR055319A1 (es) * | 2005-03-17 | 2007-08-15 | Wyeth Corp | Derivados de isoquinoleina, composiciones farmaceuticas y usos |
| US7919519B2 (en) * | 2005-11-23 | 2011-04-05 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| EP1965807A4 (en) * | 2005-11-23 | 2010-10-27 | Epix Delaware Inc | S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE |
| JP2007169194A (ja) | 2005-12-21 | 2007-07-05 | Kyorin Pharmaceut Co Ltd | ジオキサフォスフォリナン誘導体とその付加塩及びスフィンゴシン−１−リン酸（ｓ１ｐ１，ｓ１ｐ４）受容体作動薬 |
| AU2007212193A1 (en) | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
| BRPI0707873A2 (pt) | 2006-02-15 | 2011-05-10 | Allergan Inc | compostos amida, Éster, tioamida e tiol Éster do Ácido indol-3-carboxÍlico carregando grupos arila ou heteroarila tendo atividade biolàgica antagonista de recptor de esfingosina-1-fosfato (s1p) |
| JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| JP2010536791A (ja) * | 2007-08-15 | 2010-12-02 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン１−リン酸アナログ |
| WO2010017561A1 (en) | 2008-08-08 | 2010-02-11 | Otologics, Llc | Systems and methods for securing subcutaneous implantaed devices |
| ES2613739T3 (es) | 2008-10-30 | 2017-05-25 | Biogen Ma Inc. | Análogos heterobicíclicos de 1-fosfato de esfingosina |
| US8269043B2 (en) | 2008-10-30 | 2012-09-18 | Biogen Idec Ma Inc. | Bicyclic aryl sphingosine 1-phosphate analogs |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| UA113507C2 (xx) | 2011-02-07 | 2017-02-10 | Модулятори s1p |
-
2010
- 2010-05-08 UA UAA201202539A patent/UA107360C2/ru unknown
- 2010-08-05 BR BR112012002511-2A patent/BR112012002511B1/pt not_active IP Right Cessation
- 2010-08-05 EP EP10807186.1A patent/EP2461683B8/en active Active
- 2010-08-05 CN CN201510646083.6A patent/CN105330576B/zh active Active
- 2010-08-05 PT PT108071861T patent/PT2461683E/pt unknown
- 2010-08-05 IN IN1241DEN2012 patent/IN2012DN01241A/en unknown
- 2010-08-05 MY MYPI2012000304A patent/MY157707A/en unknown
- 2010-08-05 SG SG2012003117A patent/SG177675A1/en unknown
- 2010-08-05 SI SI201030960T patent/SI2461683T1/sl unknown
- 2010-08-05 DK DK10807186.1T patent/DK2461683T3/en active
- 2010-08-05 CA CA2768858A patent/CA2768858C/en active Active
- 2010-08-05 NZ NZ597596A patent/NZ597596A/en not_active IP Right Cessation
- 2010-08-05 JP JP2012523962A patent/JP5893558B2/ja active Active
- 2010-08-05 HR HRP20150792TT patent/HRP20150792T1/hr unknown
- 2010-08-05 KR KR1020127005229A patent/KR101818096B1/ko not_active Expired - Fee Related
- 2010-08-05 MX MX2012001650A patent/MX2012001650A/es active IP Right Grant
- 2010-08-05 ME MEP-2015-93A patent/ME02157B/me unknown
- 2010-08-05 WO PCT/US2010/044607 patent/WO2011017561A1/en not_active Ceased
- 2010-08-05 CN CN201080044608.4A patent/CN102548409B/zh active Active
- 2010-08-05 PL PL10807186T patent/PL2461683T3/pl unknown
- 2010-08-05 HU HUE10807186A patent/HUE025081T2/hu unknown
- 2010-08-05 AU AU2010279337A patent/AU2010279337B2/en not_active Ceased
- 2010-08-05 RS RS20150422A patent/RS54091B1/sr unknown
- 2010-08-05 ES ES10807186.1T patent/ES2539383T3/es active Active
- 2010-08-05 US US13/389,054 patent/US8802659B2/en active Active
- 2010-08-05 EA EA201200239A patent/EA024435B1/ru unknown
-
2012
- 2012-01-20 ZA ZA2012/00505A patent/ZA201200505B/en unknown
- 2012-02-02 IL IL217884A patent/IL217884A/en active IP Right Grant
- 2012-02-20 CO CO12029572A patent/CO6440523A2/es not_active Application Discontinuation
-
2014
- 2014-06-17 US US14/306,231 patent/US9186367B2/en active Active
-
2015
- 2015-07-14 SM SM201500170T patent/SMT201500170B/xx unknown
- 2015-07-23 IL IL240111A patent/IL240111B/en active IP Right Grant
- 2015-10-05 US US14/874,600 patent/US9572824B2/en active Active
-
2016
- 2016-02-24 JP JP2016032700A patent/JP6347797B2/ja active Active
-
2017
- 2017-01-03 US US15/397,421 patent/US9827258B2/en not_active Expired - Fee Related
- 2017-10-13 US US15/783,809 patent/US10166250B2/en active Active
-
2018
- 2018-01-30 JP JP2018013613A patent/JP2018123124A/ja active Pending
- 2018-11-07 US US16/182,845 patent/US20190209592A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501074A5 (https=) | ||
| HRP20150792T1 (hr) | Bicikliäśki analozi aril-sfingozin-1-fosfata | |
| JP2014500330A5 (https=) | ||
| US7875745B2 (en) | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | |
| JP2009530399A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| CA2614529A1 (en) | Pyridazinone derivatives as thyroid hormone receptor agonists | |
| JP2009519226A5 (https=) | ||
| JP2009519903A5 (https=) | ||
| HRP20220003T1 (hr) | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
| ES2958391T3 (es) | Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos | |
| JP2008504266A5 (https=) | ||
| JP2014525425A5 (https=) | ||
| JP2008508360A5 (https=) | ||
| RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
| RU2007148924A (ru) | Производные 4-или 5-аминосалицыловой кислоты | |
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| JP2021533206A5 (https=) | ||
| JP2014518853A5 (https=) | ||
| JP2010522710A5 (https=) | ||
| US20030125357A1 (en) | Therapeutic compounds for treating dyslipidemic conditions | |
| JP2021523934A5 (https=) | ||
| JP2018530582A5 (https=) | ||
| JP2021522327A5 (https=) | ||
| Arshad et al. | 1, 2, 4-oxadiazole nucleus with versatile biological applications |